Fda Panel Rejects A New Weight-Loss Drug

Rimonabant is one of the latest entrants into the weight-loss wars, but recently, this drug was unanimously rejected by an FDA panel who reviewed it for consideration of approval. This drug works on the brain to block one's appetite and desire to eat.

Concerns over depression and suicidal thoughts in patients with no history of mental illness had the FDA panel concerned enough to give Rimonabant a concordant “no” vote. Now, the FDA must rule on whether or not to accept the panel's recommendation, send the drug back for further data, or approve the drug.